In 1957, Margoshes and Vallee discovered low-molecular-mass sulfhydryl-rich proteins, the metallothioneins (MTs) [10]
It is not a drug, supplement, food, cosmetic, or medical device, and is not intended for human or veterinary use
They used a specialized method to measure gastric emptying, which involves tracking the percentage of radioactivity remaining in the stomach 15 minutes after introducing a specific substance via intragastric gavage
North America contributes the largest share to the market as the region has a structured ecosystem for adopting GLP-1 analogs
Exclusive Sections of the Report (The USPs) THERAPEUTIC EXPANSION LANDSCAPE helps you understand how GLP-1 receptor agonists are expanding beyond diabetes into obesity, cardiovascular, and neurological indications